Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00723437|
Recruitment Status : Completed
First Posted : July 28, 2008
Last Update Posted : July 28, 2008
Efficacy of systemic retinoid therapy of nail psoriasis has never been assessed objectively. Evaluate therapeutic efficacy of acitretin in patients with isolated nail psoriasis.
Open-study on thirty-six patients with moderate to severe nail psoriasis treated with acitretin.
Patients included 27 men and 9 women (mean age 41) with nail psoriasis. Intervention: Therapy consisted of acitretin 0.2 to 0.3 mg/Kg/day for 6 months.
Main Outcome Measure(s):
Clinical evaluation, NAPSI and modified NAPSI scores before therapy, every 2 months during therapy and 6 months after treatment.
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis||Drug: acitretin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin|
|Study Start Date :||January 2005|
|Actual Primary Completion Date :||January 2007|
|Actual Study Completion Date :||July 2008|
- Drug: acitretin
Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.Other Name: Neotigason
- correlate clinical improvement with % reduction in the NAPSI Score [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00723437
|Department of Dermatology University of Bologna|
|Bologna, Italy, 40138|
|Principal Investigator:||Antonella Tosti, MD||University of Bologna|